-
Patent Agency Ranking
公开(公告)号：US20160324975A1
公开(公告)日：2016-11-10
申请号：US15216870
申请日：2016-07-22
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram SHECHTER , Matityahu FRIDKIN , Haim TSUBERY
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
公开(公告)号：US20170119847A1
公开(公告)日：2017-05-04
申请号：US15391979
申请日：2016-12-28
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Tsvee LAPIDOT , Alexander KALINKOVICH , Matityahu FRIDKIN
CPC classification number: A61K38/1729 , A61K38/00 , A61K38/12 , A61K38/193 , C07K7/52 , C07K14/4723
Abstract: The invention is directed to β-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.
-
公开(公告)号：US20160280739A1
公开(公告)日：2016-09-29
申请号：US15180031
申请日：2016-06-12
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal SCHWARTZ-EISENBACH , Matityahu FRIDKIN , Michal CARDON-YAAKOV
CPC classification number: C07K7/06 , A61K9/0053 , A61K38/00 , C07K7/64
Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
Abstract translation: 本申请提供五至七个天然或非天然氨基酸的合成修饰肽以及包含它们的药物组合物，用于治疗与感觉门控功能障碍，抑郁症或认知障碍相关的行为异常的疾病或病症 ，特别是精神分裂症和阿尔茨海默病。
-
公开(公告)号：US20160122391A1
公开(公告)日：2016-05-05
申请号：US14880238
申请日：2015-10-11
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Tsvee LAPIDOT , Alexander KALINKOVICH , Matityahu FRIDKIN
IPC: C07K7/52
CPC classification number: A61K38/1729 , A61K38/00 , A61K38/12 , A61K38/193 , C07K7/52 , C07K14/4723
Abstract: The invention is directed to β-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.
Abstract translation: 本发明涉及 - 防腐素衍生肽及其在调节造血细胞，特别是造血干细胞和祖细胞活性中的用途。 具体地，本发明提供了有助于促进造血干细胞和祖细胞的移动和移植的组合物和方法。 本发明还提供了可用于治疗癌症的组合物和方法。
-
公开(公告)号：US20160000927A1
公开(公告)日：2016-01-07
申请号：US14795974
申请日：2015-07-10
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram SHECHTER , Matityahu FRIDKIN , Haim TSUBERY
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
-
-
-
Search Results
5
records
(took 0.02 seconds)
